Asthma Drug Scare at GSK
Posted on: Thursday, 14 July 2005, 18:01 CDT
Jul. 14--GlaxoSmithKline's best selling product could be cleared from pharmacists' shelves by US regulators who have raised concerns over its safety. Extensive patient tests suggest the active ingredient of GSK asthma drug Advair could be linked to a number of premature deaths.
America's Food & Drug Administration have put Advair, another Glaxo product, Serevent, and Foradil, made by Swiss giant Novartis, under scrutiny.
They may decide to bolster warnings on the packaging, but can also pull Advair and its competitors from the market. Last year the GSK drug raked in sales of £2.7bn.
The market was untroubled by the news as shares ended up 20p at 1,374p.
-----
To see more of the Daily Mail and the Financial Mail on Sunday, or to subscribe to the newspaper, go to http://www.thisismoney.com.
Copyright (c) 2005, Daily Mail, London
Distributed by Knight Ridder/Tribune Business News.
For information on republishing this content, contact us at (800) 661-2511 (U.S.), (213) 237-4914 (worldwide), fax (213) 237-6515, or e-mail reprints@krtinfo.com.
NVS, NOVN, GSK,
Source: Daily Mail
Related Articles
- FDA Wants More Data on GSK Drug
- GSK Drug Disappoints in COPD Study
- GSK Drug Suggests Potential As COPD Treatment
- GSK Drug OK'D for Cervical-Cancer Use
- Novartis Hepatitis B Treatment Beats GSK Drug in Trial
- GSK Drug Gets Priority Review for Cervical Cancer
- Positive Study for Adolor and GSK Drug
- GSK Drug Approved in Europe for Lung Cancer
- GSK Drug Soothes Restless Legs Syndrome
 |
 |
User Comments (0)
RSS Feeds